Rationale Neuropeptides are linked to the psychopathology of stimulants of abuse, principally through dopamine mechanisms. Substance P (SP) is one of these neuropeptides and is associated with both limbic and extrapyramidal dopaminergic pathways and likely contributes to the pharmacology of these stimulants. The effects of nicotine on these dopamine systems have also been extensively studied; however, its effects on the associated SP pathways have received little attention. Objectives In the present study, we elucidated the effects of nicotine treatment on limbic and extrapyramidal SP systems by measuring changes in associated SP tissue concentrations. Materials and methods Male Sprague-Dawley rats received (±)nicotine 4.0 mg/kg/day (0.8 mg/kg, intraperitoneally; five injections at 2-h intervals) in the presence or absence of selective dopamine D 1 and D 2 receptor antagonists or a nonselective nicotinic acetylcholine receptor antagonist. Results The nicotine treatment significantly but temporarily decreased substance P-like immunoreactivity (SPLI) content in the ventral tegmental area (VTA) and substantia nigra 12-18 h after drug exposure. The nicotine-mediated changes in SPLI were selectively blocked by pretreatment with mecamylamine as well as a dopamine D 1 , D 2 , or both receptor antagonists. Other brain areas that also selectively demonstrated nicotine-related declines in SPLI content included prefrontal cortex, the nucleus accumbens shell, and the very posterior caudate.
Introduction
Cigarette smoking is responsible for approximately one in five deaths in the United States accounting for approximately 438,000 deaths annually. In addition, each year, cigarette smoking costs the economy of this country over $42 billion in health care costs and lost productivity (for review, see Center for Disease Control and Prevention 2005) . Nicotine is widely regarded as the active pharmacological ingredient of tobacco that is principally responsible for addiction to this substance. The cause of addiction, as well as rewarding and cognitive properties of nicotine, is thought to be associated with the midbrain dopamine (DA) systems (Nisell et al. 1996) . Thus, the limbic DA pathways have been identified as key components in these responses due to the presence of nicotinic receptors (Aghajanian and Bunney 1977; Jones et al. 2001; Zoli et al. 2002; Picciotto 2003; Laviolette and van der Kooy 2004; Hamada et al. 2004; David et al. 2006; Quarta et al. 2007 ) and their influence on related DA functions. These DA pathways consist of cell bodies in the ventral tegmental area (VTA) that project mainly to the nucleus accumbens in the ventral striatum (Adinoff 2004 ) and the frontal cortex (Nisell et al. 1996; Cao et al. 2005) and are activated by exposure to nicotine (Role and Berg 1996; Wonnacott 1997; Marshall et al. 1997; Hamada et al. 2004; Quarta et al. 2007) . Another midbrain DA projection that is also activated by nicotine and likely contributes to the pharmacological effects of this stimulant originates in the substantia nigra, an extrapyramidal structure, and primarily projects to the dorsal striatum (Laviolette and van der Kooy 2004) .
While considerable research on the interaction between nicotinic and mesolimbic and mesocortical dopaminergic systems has been reported with the exception of a recent report that neurotensin systems are affected by nicotine treatment (Alburges et al. 2007) , there has been little study of the potential role of DA-related neuropeptide systems in mediating the neuropharmacological effects of nicotine (Naftchi et al. 1988; Singer et al. 2004; Alburges et al. 2007 ). Because of this lack of information concerning the influence of nicotine on neuropeptides, in the present research, we investigated the effects of nicotine on substance P (SP), an undecapeptide that is considered to have neurotransmitter functions and is closely aligned with both basal ganglia and limbic dopaminergic neurons.
Studies have indicated that SP is associated with cell bodies of medium spiny striatal neurons (Gerfen et al. 1990 ; Kawaguchi et al. 1990 ) that project ipsilaterally to the substantia nigra where its fibers terminate primarily within the zone reticulata of this brain region Gale et al. 1977; Brownstein et al. 1977; Mroz et al. 1977; Kanazawa et al. 1977) with collateral projections to the globus pallidus. The role of SP in the striatonigral pathway has been extensively investigated (Davies and Dray 1976; Cheramy et al. 1977; Waldmeier et al. 1978; James and Starr 1979; and is thought to tonically excite ascending nigrostriatal dopaminergic neurons (Davies and Dray 1976; Cheramy et al. 1977; Waldmeier et al. 1978; James and Starr 1979; . This type of interaction between SP and central dopaminergic systems is proposed to play an important role in mediating behavior under basal ganglia dopamine regulation (James and Starr 1979; . In addition, because the injection of this tachykinin into the VTA Kelley et al. 1989; Kelley and Delfs 1991; West and Michael 1991) , frontal cortex (Krasnova et al. 2000) , nucleus accumbens (Kalivas and Miller 1984; Nikolaev et al. 2004) , striatum (Tang et al. 1998; Preston et al. 2000; Krasnova et al. 2000) , or substantia nigra (Tan and Tsou 1988a, b) increases neuronal firing and dopamine turnover, it is not surprising that drugs which alter dopamine activity associated with these systems would also influence associated SP pathways. In fact, previous studies demonstrated that changes in the activity of the dopaminergic pathways induced by amphetamines (Ritter et al. 1984 (Ritter et al. , 1985 Sonsalla et al. 1984 Sonsalla et al. , 1986 Hanson et al. 1986a Hanson et al. , b, 2002 Bannon et al. 1987; Ujike et al. 1988) or cocaine (Alburges et al. 2000; Kraft et al. 2001 ) significantly alter SP systems in limbic and basal ganglia regions. Thus, as part of a previous report on the responses of neurotensin systems to nicotine, we also indicated that this drug reduces SP levels in the VTA (Alburges et al. 2007 ). However, in this earlier study, the response of SP pathways to nicotine was only briefly mentioned and not examined nor characterized.
To appreciate how SP function in the central nervous system (CNS) is altered by nicotine exposure, the responses of the mesocortical and mesolimbic SP systems to treatment by this stimulant were examined in detail and the underlying mechanism studied. This was accomplished by measuring the contents of substance P-like immunoreactivity (SPLI) in brain regions associated with these limbic areas, following multiple administrations of nicotine alone and in combination with other drugs. Based on previous reports, it has been demonstrated that drug-induced changes in SPLI tissue levels likely reflect alterations in SP turnover due to its release and/or synthesis (Hanson et al. 2002; Kraft et al. 2001; Loonam et al. 2003; Adams et al. 2001) .
In the present study, we observed that multiple nicotine administrations significantly reduced SPLI content in the VTA and substantia nigra as well as in the prefrontal cortex, nucleus accumbens shell, and very posterior caudate 12-18 h after treatment. All of these nicotine-mediated SP changes recovered by 48 h. In the VTA, this nicotine effect was selectively blocked by pretreatment with either a dopamine D 1 or D 2 receptor antagonist. Furthermore, in the substantia nigra, the nicotine effect was selectively blocked by a specific dopamine D 2 , but not a dopamine D 1 , receptor antagonist. In addition, pretreatment with the nonselective nicotinic acetylcholine receptor antagonist, mecamylamine, completely prevented the nicotine-induced effect on all affected SP systems examined. The significance of these findings is discussed.
Materials and methods

Animals
Male Sprague-Dawley rats (Charles River Laboratories, Raleigh, NC, USA) weighing 250-330 g were maintained in a temperature-controlled environment and cared for according to the National Institutes of Health guidelines. Animals were kept on a 12-h light/dark cycle with food and water available ad libitum. Animals were allowed to acclimate for at least 2 weeks before their use. All the experiments were performed according to the guidelines of the University of Utah Institutional Animal Care and Use Committee.
Drug treatment and tissue dissection
Following the acclimatization period, two experimental protocols were used in this study: (a) animals were injected with five administrations of either saline (1.0 mL/kg, intraperitoneally [i.p.]) or (±)nicotine freebase 4.0 mg/kg/ day (0.8 mg/kg, i.p.; five injections at 2-h intervals) and were killed 12, 18, or 48 h after treatment; (b) animals were pretreated with dopamine D 1 (SCH 23390; 0.5 mg/kg/injection, i.p.), dopamine D 2 (eticlopride; 0.5 mg/kg/injection, i.p.), or nicotine (mecamylamine; 3.0 mg/kg/injection, subcutaneously [s.c.]) receptor antagonists 15 min prior to each of the five administrations of (±) nicotine or saline and killed 18 h after treatment. Brains were removed rapidly, frozen immediately on dry ice, and stored at −80°C. For regional studies, brain areas were dissected from consecutive 1-mm thick coronal slices as previously described (Alburges et al. 2001a, b) . Based on the atlas of Paxinos and Watson (1986) , the caudate was dissected into medial anterior caudate (1.20 mm anterior to bregma), medial posterior caudate (0.20 mm anterior to bregma), and very posterior caudate (0.80 mm posterior to bregma) regions. The prefrontal cortex, nucleus accumbens (shell and core), VTA, and substantia nigra regions were also removed. All tissue samples were subsequently stored at −80°C until assayed for SPLI. The selection of the nicotine dose (0.8 mg/kg, i.p.) was based on preliminary experiments (data not shown), has been previously used (Kane et al. , 2001 (Kane et al. , 2005 Li and Kane 2003; Li et al. 2000; Matta et al. 2007; Alburges et al. 2007) , and is intended to mimic a drug exposure pattern expected from average human smokers. The time response paradigm selected in this study was based on previous studies (Ritter et al. 1984 (Ritter et al. , 1985 Sonsalla et al. 1984 Sonsalla et al. , 1986 Hanson et al. 1986a Hanson et al. , b, 2002 Alburges et al. 2000) , which demonstrated that administration of methamphetamine or cocaine produce significant changes in extrapyramidal and limbic SP systems.
Drugs
Eticlopride hydrochloride (S(−)-3-chloro-5-ethyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-hydroxy-2-methoxy-benzamide hydrochloride), SCH 23390 hydrochloride (R(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2, 3, 4, 5-tetrahydro-1H-3-benzazepine hydrochloride), mecamylamine hydrochloride, and (±)nicotine were acquired from Sigma-Aldrich (St. Louis, MO, USA). All doses were calculated as freebase of the drug and were freshly prepared in physiological saline solution (0.9% w/v NaCl, pH 7.4).
Radioimmunoassay
The solid-phase radioimmunoassay used to analyze the neuropeptide levels in this study was adapted from the methods previously described (Maidment et al. 1991; Alburges et al. 2001a, b) . Tissue samples were homogenized in 300 μL of 0.01 N HCl. The resulting homogenate was then placed in boiling water for 10 min in order to inactivate peptidases. Homogenates were centrifuged (17,000×g) for 30 min. Supernatant was then collected and an aliquot was used to determine the total protein for each tissue sample by the method of Bradford (1976) . The remaining sample was lyophilized overnight and stored at −80°C until the radioimmunoassay was performed. The concentration of neuropeptide was determined with a modified solid-phase radioimmunoassay technique described for neurotensin by Maidment et al. (1991) . Lyophilized samples were reconstituted in 300 μL phosphate-buffered saline (pH 7.4) containing 0.1% (w/v) gelatin and 0.1% (v/v) Triton X-100. Nunc-Immunoplates (ISC BioExpress, Kaysville, UT, USA) were incubated overnight at 4°C with 50 μL of protein G solution (50 ng/ 100 μL in 0.1 M sodium bicarbonate; pH 9.0). After washing the wells three times with wash buffer [0.15 M K 2 HPO 4 , 0.02 M NaH 2 PO 4 , 0.2 mM ascorbic acid, 0.2% (v/v) Tween-20, and 0.1% (w/v) sodium azide; pH 7.5], 25 μL of a highly selective antiserum for SP was diluted in assay buffer [same as wash buffer containing 0.1% (w/v) gelatin] to 1:200,000. Following addition of SP antisera, wells were incubated for 4 h at room temperature in order to allow the attachment of antibody to the protein G-coated surface. After incubation, wells were washed three times and 25 μL of sample or standard(s) were added to each well and incubated at room temperature overnight. The next day, 25 μL of the labeled peptide ([ 125 I]substance P) diluted with assay buffer to approximately 6,500 dpm per 25 μL was added to the wells and incubated for 2 h at room temperature. After incubation, wells were washed, separated, and placed in 12×75-mm polypropylene tubes and counted in a five-channel Packard Cobra II Auto-Gamma counter (Packard Instrument, Meriden, CT, USA). The total and nonspecific binding were defined by adding 25 μL of the labeled peptide to protein G-untreated and -treated wells, respectively. Quantities of neuropeptide immunoreactivity were determined by comparing bound to free [
125 I] substance P in each sample to a standard curve (from 0.5 to 125 pg/assay tube). The reproducibility of the assay was evaluated using cerebellum tissue spiked with 62 and 250 pg of each peptide. This technique has been demonstrated to be very reproducible, resulting in less than 10% variability between assays and less than 5% between sample and standard duplicates. The procedure allowed reliable detection of 500 fg of SPLI per sample.
Antiserum
The SP anstiserum was raised in New Zealand White rabbits as previously described (Letter et al. 1987; Ritter et al. 1984; Wagstaff et al. 1996) . This antiserum recognizes the SP carboxy terminus and is highly selective, expressing no cross-reactivity with 1,000-fold excess concentrations of other endogenous neuropeptides such as dynorphin A, metenkephalin, cholecystokinin, or substance K.
Statistical analysis
Results from these experiments are expressed as percentages of their respective controls in order to facilitate comparisons between groups (mean values±SEM). The control values (picograms of SPLI per milligram of protein) for each experiment are indicated in the corresponding figure legend. Differences between means were analyzed using one-way analysis of variance followed by Fisher's protected least significant difference (PLSD). Differences were considered significant when the probability that they were zero was less than 5%.
Results
In order to determine if nicotine treatment influences limbic and/or basal ganglia SP systems, the effect of multiple administrations (five injections, 2-h intervals) of (±)nicotine (0.8 mg/kg/injections, i.p.) on SPLI contents in the VTA and substantia nigra were evaluated after 12, 18, and 48 h (Fig. 1) . This nicotine treatment significantly reduced SPLI in the VTA at both 12 and 18 h after drug administration (56% and 53% of control, respectively; one-way ANOVA: P<0.001 in both cases; Fig. 1a ). In the adjacent substantia nigra, the nicotine treatment also significantly decreased SPLI concentrations (76% of control; one-way ANOVA: P<0.05) at 18 h following injection (Fig. 1b) . After 48 h, the SPLI contents in both brain regions returned to control. In contrast, a single dose of (±)nicotine (from 0.4 to 3.2 mg/kg, i.p.) did not cause any significant changes in SPLI concentrations in these brain regions up to 24 h after treatment (data not shown).
The role of DA subtypes and nicotinic receptors in the nicotine-induced changes in limbic and basal ganglia SP systems was evaluated by pretreating animals with selective DA D 1 (SCH 23390) and DA D 2 (eticlopride) receptor antagonists and with the nonselective nicotinic receptor antagonist mecamylamine prior to each nicotine injection. The DA receptor antagonists and the nicotinic receptor antagonist alone did not significantly affect SPLI levels in any of the regions examined. As previously observed, the administration of nicotine significantly decreased the content of SPLI in the VTA (Fig. 2 ) and substantia nigra (Fig. 3) . In the VTA, pretreatment with either a dopamine D 1 or D 2 receptor antagonist completely prevented the nicotine-induced SP effect (Fig. 2) . However, in the substantia nigra, the antagonism of dopamine D 2 , but not dopamine D 1 , receptors completely blocked the nicotineinduced decreases in SPLI concentrations (Fig. 3) . Pretreatment with the nonselective nicotinic acetylcholine receptor antagonist mecamylamine also prevented the nicotineinduced decreases in SPLI content in both VTA and substantia nigra (Figs. 2 and 3, respectively) . Fig. 1 Temporal effects of multiple nicotine administration on SPLI content in the VTA (a) and substantia nigra (b). Animals were administered five injections of (±)nicotine (0.8 mg/kg/injection, i.p., 2-h intervals) or saline (control) and killed 12, 18, or 48 h following treatment. Results are expressed as percentages of control and represent the mean values±SEM (n=8 for saline and 9 for drugtreated animals per group). The average control value of SPLI concentration for the VTA and substantia nigra were 1,131±132 and 7,420±779 pg/mg protein, respectively. *P<0.05, ***P<0.001 vs. control
The temporal response of SP systems to nicotine administration in the terminal region of mesocortical projections (i.e., prefrontal cortex) was evaluated using the same nicotine treatment described in Fig. 1 . The tissue content of SPLI in the prefrontal cortex (Fig. 4a) was significantly decreased to 57% of control (one-way ANOVA: P < 0.05) 18 h following the last nicotine administration. In order to assess the SP response in the terminal region of mesolimbic DA projections, the shell of the nucleus accumbens was examined (Fig. 4b) , and SPLI concentrations were significantly reduced to 73% and 74% of control (one-way ANOVA: P<0.05 in both cases) at 12 and 18 h after nicotine administrations, respectively. In contrast, no significant changes in SPLI concentrations were observed in the core of the nucleus accumbens from the same animals (Fig. 4c) .
The time-related effects of nicotine treatment on the SPLI content in the parallel terminal regions of the basal ganglia system were also evaluated. The tissue content of SPLI was significantly decreased in the very posterior caudate to 51% of the control (one-way ANOVA: P<0.05) 18 h after drug treatment, but returned to the control levels by 48 h (Fig. 5c) . However, SPLI contents in either the anterior or posterior of the medial caudate were not significantly different from control at any of the times examined (Fig. 5a,b) .
Discussion
It is known that nicotine exposure through tobacco smoking or by administration of the pure drug has significant effects on the activity of limbic systems contributing to both the rewarding (and abuse liability) and cognitive features of this stimulant (Maskos et al. 2005; Singer et al. 2004 ). These properties of nicotine treatment are almost certainly associated with DA release from limbic structures such as the nucleus accumbens (Nisell et al. 1994; Sziraki et al. 2002; Ferrari et al. 2002; Rowell and Volk 2004) and the prefrontal cortex (Nisell et al. 1996; Cao et al. 2005) due to a high concentration of nicotinic receptors subunits such as alpha 4 and 7 and beta 2 on DA neurons originating from the VTA (Maskos et al. 2005; Klink et al. 2001; Wu et al. 2004; Nisell et al. 1994; Quarta et al. 2007 ).
While considerable details have been reported about nicotinic and dopaminergic interactions in limbic structures, there has been little research examining nicotine's effects on other VTA-related neuroregulatory systems, such as the neuropeptides, that have also been demonstrated to help regulate DA efferent pathways and associated functional outcomes. In this regard, we recently reported a study that demonstrated limbic and extrapyramidal neurotensin systems are significantly altered in the VTA, prefrontal cortex, and substantia nigra after exposure to nicotine (Alburges et al. 2007) . Fig. 2 Effects of selective dopamine receptor and nicotinic acetylcholine receptor antagonists on nicotine-induced changes in SPLI content in the VTA. Animals were given five administrations of (±) nicotine (N; 0.8 mg/kg/injection, i.p., 2-h intervals) or saline (S; control), alone or 15 min after administration of SCH 23390 (SCH; dopamine D 1 receptor antagonist; 0.5 mg/kg/injection, i.p.), eticlopride (ETI; dopamine D 2 receptor antagonist; 0.5 mg/kg/injection, i.p.), or mecamylamine (MEC; nicotinic acetylcholine receptor antagonist; 3.0 mg/kg/injection, s.c.). Animals were killed 18 h following the last treatment. Values represent the means±SEM expressed as percentages of control (n=8 for control and 9 for drug-treated animals per group). The control value±SEM for SPLI concentrations (picograms per milligram protein) was 1,094±130. *P<0.05 vs. all other groups Fig. 3 Effects of selective dopamine receptor and nicotinic acetylcholine receptor antagonists on nicotine-induced changes in SPLI content in the substantia nigra. Animals were given five administrations of (±)nicotine (N; 0.8 mg/kg/injection, i.p., 2-h intervals) or saline (S; control), alone or 15 min after administration of dopamine D 1 , D 2 or nicotinic acetylcholine receptor antagonists (as described for Fig. 2 ). Animals were killed 18 h following the last treatment. Values represent the means±SEM expressed as percentages of control (n= 8 for control and 9 for drug-treated animals per group). The control value±SEM for SPLI concentrations (picograms per milligram protein) was 7,325±565. *P<0.05 vs. all other groups To compliment the neurotensin observations and to follow-up an observation in that report that nicotine can also alter SPLI levels in the VTA (Alburges et al. 2007 ), the present studies examined in detail which limbic and extrapyramidal SP systems are influenced by nicotine treatment and determined the role of dopamine mechanisms in these effects. Substance P in limbic and extrapyramidal structures has been associated with biochemical and behavioral changes when injected into the VTA Elliott et al. 1986; Cador et al. 1989; West and Michael 1991; Kelley and Delfs 1991; Zhou and Nyberg 2002) , prefrontal cortex (Krasnova et al. 2000) , nucleus accumbens (Iversen 1982; Kalivas and Miller 1984; Huston and Hasenohrl 1995; Schildein et al. 1998; Nikolaev et al. 2004) , and substantia nigra (Tan and Tsou 1988a, b) . There is also evidence that SP plays a central role in mediating the abstinence reaction to psychoactive drugs such as opioids (Tiong et al. 1992; Kreeger and Larson 1996; Murtra et al. 2000) and antidepressants (Jones and Olpe 1984) . Thus, alteration of withdrawal symptoms from these drugs may be mediated by the interaction of SP with the mesocorticolimbic dopaminergic systems (Zhou and Nyberg 2002; Zhou et al. 2003 Zhou et al. , 2004 , suggesting the possibility of using SP-targeted psychopharmacology to treat the adverse effects of other DA-related psychoactive drugs such as nicotine.
The rationale for selecting limbic and extrapyramidal structures to study the nicotine effect was based on the close association between these dopamine projections and substance P-containing neurons (Cheramy et al. 1977; Gerfen et al. 1990; Lu et al. 1998 ) and the possible involvement of SP with both limbic and extrapyramidal dopaminergic pathways in the reward and addiction process of stimulant of abuse. Thus, a SP pathway comparable to that associated with the basal ganglia is also linked with mesolimbic dopaminergic neurons. These SP-containing cell bodies are found in the medial habenular nucleus and project to the VTA and terminate near mesolimbic dopaminergic neurons (Lindvall et al. 1977; Mroz et al. 1977; Kanazawa et al. 1977) . These biochemical and electrophysiological evidences suggest that SP induces some of its effects through the activation of the mesocortical and mesolimbic dopamine systems.
In order to understand better the function of SP systems in the VTA, especially as it relates to nicotine effects, we determined the actions of nicotine injections on SPLI tissue levels. We selected the nicotine dose (0.8 mg/kg/injection) based on: (1) our preliminary studies where 0.4 to 3.2 mg/kg, i.p. nicotine was administered and doses of 1.6 and Fig. 4 Temporal response of multiple nicotine administration on SPLI content in VTA-related brain regions such as the prefrontal cortex (a), nucleus accumbens shell (b), and nucleus accumbens core (c). Animals were given injections of (±)nicotine (as described for Fig. 1 ) or saline (control) and killed 12, 18, or 48 h following treatment. Results are expressed as percentages of control and represent mean values±SEM (n=8 for control and 9 for drug-treated animals per group). The average control value of SPLI concentration for the prefrontal cortex, nucleus accumbens shell, and nucleus accumbens core were 319±46, 2,189±159, and 1418±153 pg/mg protein, respectively. *P<0.05 vs. control b 3.2 mg/kg, i.p. were found to cause motor dysfunction and even sometimes seizures (data not shown) and (2) an administration paradigm previously reported (Kane et al. , 2001 (Kane et al. , 2005 Li and Kane 2003; Li et al. 2000; Matta et al. 2007; Alburges et al. 2007 ) and intended to mimic the pattern of nicotine exposure that would occur in the typical heavy smoker.
We observed that exposure to nicotine rapidly (12 to 18 h) but reversibly (back to control levels by 48 h) reduced SPLI content in the VTA (Fig. 1a) . We confirmed this SP change was linked to the nicotinic and dopaminergic systems by the observation that the effect was blocked by a nicotinic and both DA D 1 and D 2 receptor antagonists (Fig. 2) . These conclusions were supported by the previous finding that the DA-releasing drug methamphetamine also reduces SPLI levels in the VTA (Hanson et al. 1986b ). For comparison, a similar treatment by nicotine reduced the level of neurotensin in this same limbic structure through nicotinic and dopaminergic mechanisms, although in contrast to the corresponding SP response, the neurotensin decreases were mediated by only D 2 , but not D 1 , receptor mechanisms (Alburges et al. 2007 ).
Our observation that nicotine treatment reduced the SPLI levels in the VTA is consistent with the interpretation that stimulation of nicotinic receptors releases SP, resulting in an increase in SP turnover and depletion of tissue levels. Because SCH 23390 or eticlopride pretreatments blocked this response, it is likely that the nicotine-induced SP changes were mediated by DA release activating D 1 and D 2 receptors (Hanson et al. 2002; Alburges et al. 2007) . If stimulation of nicotinic receptors does increase SP release in the VTA as suggested by these findings, it is possible that SP plays a significant role in mediating some of the consequences of nicotine consumption on associated limbic function. This conclusion is consistent with findings that SP in the VTA: (1) has an excitatory effect on neurons found in this brain region (Korotkova et al. 2006) ; (2) is linked with drug-seeking behavior (Placenza et al. 2004 ); (3) may contribute to the regulation of DA release in the nucleus accumbens caused by nicotine treatment (Zhou and Nyberg 2002) ; (4) contributes to locomotor activity mediated by mesolimbic systems (Elliott et al. 1992) ; and (5) affects feeding behavior (Cador et al. 1986 ). Since nicotine administration can influence all of the properties listed above, perhaps SP systems contribute to these effects.
Due to similarities with the limbic systems, the SP projections associated with the striatonigral pathway (Cheramy et al. 1977; Waldmeier et al. 1978; Haber and Nauta Fig. 5 Temporal response of multiple nicotine administration on SPLI content in the substantia nigra-caudate nucleus projection such as the medial anterior caudate (a), medial posterior caudate (b), and very posterior caudate (c). Animals were given injections of (±)nicotine (as described for Fig. 1 Gerfen et al. 1990; Kawaguchi et al. 1990) were also evaluated by measuring nigral SPLI levels after nicotine treatment. Although the nigral effect did not appear to be as robust as the SP changes in the VTA, nicotine exposure also did reversibly reduce SPLI levels in this tissue at 18 h (Fig. 1b) . Like the SPLI changes in the VTA, the nigral SP response was blocked both by the nicotinic and D 2 antagonists, but differed in that blockade of the D 1 receptor did not alter the nigral response (Fig. 3) . These findings suggest that the nigral SP effects were mediated by nicotinic receptors likely causing release of DA, stimulating D 2 receptors, and effecting changes in the striatonigral SP pathway.
Because nicotine caused changes in SPLI content through DA receptor mechanisms in both the VTA and substantia nigra, we tested the possibility that exposure to nicotine also alters SP systems in other brain regions where nicotine exposure results in DA release (Emmett and Greenfield 2005; Singer et al. 2004; Janhunen and Ahtee 2004) . Specifically, we measured the effects of nicotine treatment on SPLI levels in DA terminal regions for cell bodies originating in the VTA and the substantia nigra. Our findings revealed that the same multiple nicotine administrations that influenced SPLI levels in the regions of the DA cell bodies similarly reduced SPLI content in the prefrontal cortex (Fig. 4a) , nucleus accumbens shell (Fig. 4b) , and very posterior caudate (Fig. 5c ) in a reversible manner, but had no significant effect on SPLI content in the nucleus accumbens core (Fig. 4c) or the medial anterior and posterior caudate (Fig. 5a,b ). These observations demonstrate that the SP responses to nicotine exposure are selective, even within limbic and extrapyramidal systems. It may be relevant that previous reports suggest acute nicotine exposure (such as the paradigm used in the present study) tends to increase release of DA in the nucleus accumbens shell and other limbic areas, whereas chronic exposure causes a shift in DA responses to more of the accumbens core region (Di Chiara 2000) . This possibly explains why we observed SP changes in the shell, but not the core, after this acute exposure to nicotine. As previously described, nicotine administration has been shown to induce DA release in the frontal cortex (Nisell et al. 1996; Cao et al. 2005 ) explaining why SP systems are affected in this cognitive-related brain region. As for the pattern of SP responses in extrapyramidal structures, there are no known studies that have attempted to compare variable effects of nicotine on DA release in the different caudate regions.
The decreases in SPLI concentration (30-50%) in the prefrontal cortex, VTA, and substantia nigra seen after multiple nicotine administration are in contrast with the findings from Naftchi et al. (1988) . They found no changes in SPLI content in these brain regions following nicotine treatment. These distinctions are likely due to differences in the experimental drug paradigm used. In our study, we administered a multiple dosing protocol (more consistent with clinical exposures associated with traditional smoking patterns) in which animals were injected every 2 h for five doses and then killed 12, 18, and 48 h after last nicotine treatment. Naftchi et al. (1988) only administered a single injection of nicotine and killed the animals 10 min after the nicotine treatment. It seems likely that multiple administrations of nicotine are required to induce SPLI changes in these brain areas. On the other hand, in agreement with the previous finding (Naftchi et al. 1988) , we found that this nicotine treatment also decreased SPLI content in the posterior caudate and nucleus accumbens shell (but not core).
Although the present study examined the effect of multiple nicotine administrations on limbic and extrapyramidal SP systems, previous studies demonstrated that other psychostimulants such as the amphetamines and cocaine also alter SP pathways in these CNS regions via dopamine mechanisms. For example, different from the nicotine effects reported herein, high doses of methamphetamine and cocaine elevate SPLI levels in the caudate nucleus and nucleus accumbens (Sonsalla et al. 1984 (Sonsalla et al. , 1986 Ritter et al. 1984 Ritter et al. , 1985 Alburges et al. 2000; Hanson et al. 1986a Hanson et al. , 2002 through dopamine mechanisms (Ritter et al. 1985; Sonsalla et al. 1986; Alburges et al. 2000) . Similar highdose treatment with these drugs also stimulates the synthesis of SP as demonstrated by an increase in the mRNA for preprotachykinin (Adams et al. 2001) , possibly contributing to the accompanying elevation in peptide levels. It is noteworthy and likely relevant to these current findings that a similar high dose of methamphetamine (10 mg/kg) does not alter the release of SP in the substantia nigra. In contrast, a low dose of methamphetamine (0.5 mg/kg) which doubles the release of SP in the substantia nigra has an opposite effect and reduces the SPLI levels in several extrapyramidal brain regions (Hanson et al. 2002) . As shown in the current study, nicotine also decreased SPLI tissue levels in the substantia nigra as well as other extrapyramidal and limbic structures, suggesting that these nicotine-induced changes were associated with SP release, as was the case with the low-dose methamphetamine treatment.
In summary, administration of nicotine in a dose and pattern resembling that associated with heavy smoking substantially influences SP systems linked with mesocortical and mesolimbic DA pathways. Thus, these treatments of nicotine caused 30-50% reductions in both the regions of DA cell bodies (VTA) and terminals (prefrontal cortex and nucleus accumbens shell). In a similar but somewhat diminished fashion, we observed that these nicotine treatments also reduced SPLI in some regions associated with the extrapyramidal DA cell bodies and terminal. These reductions in SPLI tissue content likely reflect a nicotineinduced release of SP and increased turnover, suggesting that these SP systems contribute to the limbic and extrapyramidal functional consequences of heavy nicotine consumption.
